title: Activation of PPAR-gamma by carbon monoxide from CORM-2 leads to the inhibition of iNOS but not COX-2 expression in LPS-stimulated macrophages.
abstract: The effect of CO on the expression of iNOS and COX-2 was investigated by using a CO-releasing molecule (CORM)-2 in LPS-activated RAW 264.7 cells in vitro. Interestingly, CORM-2 significantly inhibited iNOS (NO) but not COX-2 (PGE(2)) expression. PPAR-gamma activators such as troglitazone, GW1929, and 15-deoxy-Delta12, 14- prostaglandin J(2) showed preferential inhibitory effect on iNOS over COX-2 expression in LPS-activated macrophages. The same effect was shown in lung tissues (iNOS, COX-2) and serum (NO, PGE(2)) when administered of CORM-2 in LPS-induced septic mice, indicating that CO derived from CORM-2 differentially regulates iNOS and COX-2 through PPAR-gamma activation under inflammation state.
authors.affiliation: Department of Pharmacology, School of Medicine and Institute of Life Sciences, Biomedical Center (BK21), Gyeongsang National University, Jinju 660-751, Korea.
authors.forename: Konstantin
authors.initials: K
authors.lastname: Tsoyi
authors.forename: Yu Mi
authors.initials: YM
authors.lastname: Ha
authors.forename: Young Min
authors.initials: YM
authors.lastname: Kim
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Lee
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Hye Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Han Geuk
authors.initials: HG
authors.lastname: Seo
authors.forename: Jae Heun
authors.initials: JH
authors.lastname: Lee
authors.forename: Ki Churl
authors.initials: KC
authors.lastname: Chang
mesh_terms: D000818:Animals; D002248:Carbon Monoxide / Q000494:pharmacology*; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D019446:Endotoxemia / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D008070:Lipopolysaccharides / Q000502:physiology*; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D009942:Organometallic Compounds / Q000378:metabolism / Q000494:pharmacology*; D047495:PPAR gamma / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D009942:Organometallic Compounds; D047495:PPAR gamma; C447082:tricarbonyldichlororuthenium (II) dimer; D002248:Carbon Monoxide; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2
references.citation: Biochem Biophys Res Commun. 2008 Mar 14;367(3):674-9
references.pmid: 18174021
references.citation: FASEB J. 2004 May;18(7):854-6
references.pmid: 15001560
references.citation: J Clin Invest. 2008 Jan;118(1):239-47
references.pmid: 18060048
references.citation: Curr Pharm Des. 2008;14(5):465-72
references.pmid: 18289073
references.citation: J Biol Chem. 1994 Feb 18;269(7):4705-8
references.pmid: 7508926
references.citation: Br J Pharmacol. 1999 Sep;128(2):357-64
references.pmid: 10510445
references.citation: Life Sci. 2008 Mar 12;82(11-12):600-7
references.pmid: 18262205
references.citation: Cell Mol Neurobiol. 2007 Nov;27(7):909-21
references.pmid: 17902045
references.citation: Am J Respir Cell Mol Biol. 2006 Aug;35(2):220-6
references.pmid: 16543610
references.citation: J Immunol. 2009 Mar 15;182(6):3809-18
references.pmid: 19265160
references.citation: Neurochem Res. 2009 Mar;34(3):430-7
references.pmid: 18668365
references.citation: Am J Respir Crit Care Med. 2008 Jun 1;177(11):1223-32
references.pmid: 18356564
references.citation: Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2046-50
references.pmid: 7510883
references.citation: Rheumatology (Oxford). 2008 Sep;47(9):1323-8
references.pmid: 18621749
references.citation: Neuroscience. 2008 Feb 19;151(4):1104-11
references.pmid: 18248914
references.citation: Microbiology (Reading). 2009 Mar;155(Pt 3):813-824
references.pmid: 19246752
references.citation: Br J Pharmacol. 2005 Jul;145(6):800-10
references.pmid: 15880142
references.citation: Nat Med. 2000 Apr;6(4):422-8
references.pmid: 10742149
references.citation: Circ Res. 2002 Feb 8;90(2):E17-24
references.pmid: 11834719
references.citation: Mol Cell Biochem. 2000 Jun;209(1-2):113-8
references.pmid: 10942208
references.citation: FASEB J. 2008 Sep;22(9):3380-8
references.pmid: 18556460
references.citation: Cell Signal. 2008 Oct;20(10):1839-47
references.pmid: 18634870
references.citation: Immunity. 2006 May;24(5):601-10
references.pmid: 16713977
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):493-502
references.pmid: 18563392
references.citation: Physiol Rev. 2006 Apr;86(2):583-650
references.pmid: 16601269
references.citation: J Biol Chem. 2009 Feb 13;284(7):4516-24
references.pmid: 19091747
references.citation: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6712-7
references.pmid: 12740443
references.citation: Biomed Pharmacother. 2008 Nov;62(9):630-6
references.pmid: 18325727